Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Reports Q2 2025 Financial Results and Provides Business Update
Summary
Crinetics Pharmaceuticals, Inc. reported its financial results for the second quarter ended June 30, 2025. The company highlighted consistent progress with the FDA review for its NDA for paltusotine, an investigational treatment for acromegaly, which has a PDUFA date of September 25, 2025. Additionally, Crinetics reported strong cash reserves of $1.2 billion as of June 30, 2025, which is expected to fund its operations into 2029. The company also provided updates on its pipeline, including progress on the global development program for atumelnant, with plans to initiate multiple Phase 3 studies in the second half of 2025.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement